Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EBITDA (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed EBITDA for 3 consecutive years, with -$28.1 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 6.74% to -$28.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$29.8 million through Dec 2025, up 38.6% year-over-year, with the annual reading at -$29.8 million for FY2025, 38.6% up from the prior year.
  • EBITDA hit -$28.1 million in Q4 2025 for Immunocore Holdings, down from -$3.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $12.0 million in Q3 2024 to a low of -$28.1 million in Q4 2025.
  • Historically, EBITDA has averaged -$9.6 million across 3 years, with a median of -$10.5 million in 2023.
  • Biggest YoY gain for EBITDA was 185.32% in 2024; the steepest drop was 4508.57% in 2024.
  • Year by year, EBITDA stood at -$572000.0 in 2023, then plummeted by 4508.57% to -$26.4 million in 2024, then decreased by 6.74% to -$28.1 million in 2025.
  • Business Quant data shows EBITDA for IMCR at -$28.1 million in Q4 2025, -$3.6 million in Q3 2025, and -$3.8 million in Q2 2025.